Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
The adipocyte enhancer binding protein 1 is a transcriptional repressor with carboxypeptidase (CP) activity. Zusätzlich bieten wir Ihnen AEBP1 Kits (12) und AEBP1 Proteine (3) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 47 products:
Cow (Bovine) Polyclonal AEBP1 Primary Antibody für IHC, WB - ABIN2777370
Kim, Gieske, Trudgen, Hudgins-Spivey, Kim, Krust, Chambon, Jeong, Blalock, Ko: Identification of estradiol/ER?-regulated genes in the mouse pituitary. in The Journal of endocrinology 2011
ACLP stimulates the fibroblast-to-myofibroblast transition by promoting SMA (zeige SMN1 Antikörper) expression via TGFbeta (zeige TGFB1 Antikörper) signaling and promoting collagen expression through a TGFbeta (zeige TGFB1 Antikörper) receptor-independent pathway.
There is no statistically significant differences in the frequency of variants in AEBP1 among the gastroschisis case group compared to a Caucasian control group.
Most ACLP knockout mice die perinatally due to abdominal issues.
Both cellular proliferation and survival were affected in AEBP1-silenced U87MG and U138MG cell lines and a significant percentage of these cells were directed towards apoptosis.
This review focuses on the recently reported regulatory functions that adipocyte enhancer-binding protein 1 (AEBP1) exerts on PPARgamma1 and LXRalpha (zeige NR1H3 Antikörper) transcriptional activity in the context of macrophage cholesterol homeostasis and inflammation.
Transgenic overexpression of AEBP1 during adipogenesis coupled with a high-fat diet results in massive obesity in female transgenic mice via adipocyte hyperplasia.
ACLP and its discoidin-like domain may be novel targets for anti-myofibroblast-based therapies for the treatment of pulmonary fibrosis.
Stromal adipocyte enhancer-binding protein (AEBP1) promotes mammary epithelial cell hyperplasia via proinflammatory and hedgehog (zeige SHH Antikörper) signaling
Data suggest that macrophage AEBP1 plays critical regulatory roles in atherogenesis, and it may serve as a potential therapeutic target for the prevention or treatment of atherosclerosis.
Results describe the pathophysiological features of gastroschisis in aortic carboxypeptidase-like protein knockout mice and to characterize the neuromuscular development of the eviscerated intestine.
MAPK (zeige MAPK1 Antikörper) regulates the transcriptional activity of AEBP1 by a novel dual mechanism, in which MAPK (zeige MAPK1 Antikörper) interaction enhances and subsequent phosphorylation decreases the DNA-binding ability of AEBP1
AEBP1 plays critical regulatory roles in macrophage cholesterol homeostasis, foam cell formation, and proinflammation.
NF-kappaB (zeige NFKB1 Antikörper) activity is modulated by means of protein-protein interaction involving AEBP1 and IkappaBalpha (zeige NFKBIA Antikörper).
AEBP1 negatively regulates adipose tissue PTEN (zeige PTEN Antikörper) levels and has a key functional role in modulation of in vivo adiposity.
Adipocyte enhancer-binding protein 1 (AEBP1) is up-regulated during monocyte differentiation.
The adipocyte enhancer binding protein 1 is a transcriptional repressor with carboxypeptidase (CP) activity. This protein binds to a regulatory sequence, adipocyte enhancer 1 (AE-1), located in the proximal promoter region of the adipose P2 (aP2) gene, which encodes the adipocyte fatty-acid binding protein. It is characterized as a member of the regulatory B-like CP family. This protein seems to be activated by a novel mechanism, whereby the direct binding of DNA enhances its protease activity. Adipocyte-enhancer binding protein 1 may play a role in differentiated vascular smooth muscle cells.
AE binding protein 1
, adipocyte enhancer-binding protein 1
, aortic carboxypeptidase-like protein
, AE-binding protein 1